S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
NASDAQ:AIKI

AIkido Pharma (AIKI) Stock Price, News & Analysis

$2.11
+0.01 (+0.48%)
(As of 02/29/2024 ET)
Today's Range
$2.01
$2.16
50-Day Range
$2.02
$2.62
52-Week Range
$3.31
$11.48
Volume
5,093 shs
Average Volume
79,326 shs
Market Capitalization
$11.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AIKI stock logo

About AIkido Pharma Stock (NASDAQ:AIKI)

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

AIKI Stock Price History

AIKI Stock News Headlines

Royalty Pharma PLC
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Dominari Holdings Inc. Releases Shareholder Update
Kyle Wool Appears on Fox Business
Dominari Holdings Appoints George Way As CFO
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Dominari Holdings Provides Business Update
AIkido Share Repurchase Continues
AIkido Purchases More Shares
Share Repurchase Program Continues
AIkido Pharma Continues Share Repurchase Program
AIkido Pharma Provides Update on Share Repurchase Program
AIkido Pharma Confirms Receipt of Unsolicited Offer
Aikido Pharma Inc
See More Headlines
Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:AIKI
Employees
4
Year Founded
1967

Profitability

Net Income
$-7,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$19.27 per share

Miscellaneous

Free Float
5,013,000
Market Cap
$11.57 million
Optionable
Not Optionable
Beta
0.93

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Anthony C. Hayes Esq. (Age 54)
    CEO, Principal Financial Officer, Principal Accounting Officer & Director
    Comp: $960k
  • Mr. Darrell Dotson
    VP of Drug Devel. & Gen. Counsel
  • Mr. Carlos Aldavero
    Pres of Dominari Financial














AIKI Stock Analysis - Frequently Asked Questions

How have AIKI shares performed in 2024?

AIkido Pharma's stock was trading at $2.59 at the beginning of 2024. Since then, AIKI stock has decreased by 18.5% and is now trading at $2.11.
View the best growth stocks for 2024 here
.

When did AIkido Pharma's stock split?

AIkido Pharma shares reverse split on the morning of Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of AIkido Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIkido Pharma investors own include Biocept (BIOC), AIM ImmunoTech (AIM), Nuwellis (CHFS), Foresight Autonomous (FRSX), iBio (IBIO), Exela Technologies (XELA), Bionano Genomics (BNGO), Check-Cap (CHEK), Digital Ally (DGLY) and Purple Biotech (KTOV).

How do I buy shares of AIkido Pharma?

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AIkido Pharma have any subsidiaries?
The following companies are subsidiares of AIkido Pharma: Hoth Therapeutics.
Read More
This page (NASDAQ:AIKI) was last updated on 3/1/2024 by MarketBeat.com Staff